Internal Medicine, Infectious Disease · South Miami, FL
NPI
1801859988
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
7000 SW 62nd Ave, Suite 320
South Miami, FL, 33143
Phone (305) 740-6071
Groups this clinician bills Medicare through
Medicare paid, 2024
$13K
160 services
Medicare patients, 2024
46
Average age 72
Drug cost, 2024
$2.9M
1,163 prescriptions
Company payments, 2025
$2,818
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raj B Uttamchandani was code 99214 (office e&m - established), 84 times for 36 patients. In total Raj B Uttamchandani billed 160 services in 15 codes, and Medicare paid $13K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-07-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 84 | 36 | $101.31 | $8,510 |
By year: 2022 $11K for 153 services; 2023 $11K for 138 services; 2024 $13K for 160 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 16 | 14 | $2.96 | $47.43 |
Medicare prescription drug claims, 2024
In 2024, the drug Raj B Uttamchandani prescribed most often to Medicare patients was Juluca (Dolutegravir/Rilpivirine), with 222 prescriptions and refills. In total Raj B Uttamchandani wrote 1,163 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Juluca Dolutegravir/Rilpivirine | 222 | 222 | 21 | $782K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 114 | 114 | Under 11 | $468K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 109 | 109 | Under 11 | $414K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 60 | 60 | Under 11 | $255K |
| Dovato Dolutegravir Sodium/Lamivudine | 60 | 68 | Under 11 | $198K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 50 | 50 | Under 11 | $239K |
| Descovy Emtricitabine/Tenofov Alafenam | 40 | 40 | Under 11 | $91K |
| Tivicay Dolutegravir Sodium | 38 | 38 | Under 11 | $91K |
| Acyclovir Generic | 32 | 66 | Under 11 | $539 |
| Amikacin Sulfate Generic | 31 | 31 | Under 11 | $3,357 |
| Prezcobix Darunavir/Cobicistat | 25 | 25 | Under 11 | $61K |
| Methenamine Hippurate Generic | 23 | 51 | Under 11 | $2,388 |
| Cefoxitin Cefoxitin Sodium | 20 | 20 | Under 11 | $4,667 |
| Ritonavir Generic | 18 | 18 | Under 11 | $613 |
| Tigecycline Generic | 18 | 18 | Under 11 | $11K |
Brand drugs: 787 claims; generic drugs: 376 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raj B Uttamchandani $2,818 ($2,818 in general payments such as food, travel and fees) from 9 companies. The largest payer was ViiV Healthcare Company with $1,218.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 51 | $1,218 |
| Gilead Sciences, Inc. GILD | 22 | $670 |
| Insmed, Inc. INSM | 11 | $272 |
| Merck Sharp & Dohme LLC MRK | 6 | $177 |
| Cumberland Pharmaceuticals, Inc. CPIX | 6 | $175 |
| Paratek Pharmaceuticals, Inc. | 5 | $120 |
| Melinta Therapeutics, LLC | 3 | $81.49 |
| Theratechnologies Inc. THTX | 2 | $79.8 |
| CorMedix Inc. CRMD | 1 | $25.2 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.